Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 10/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 8/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.40 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5083021 | 0.98 | ADORA1 (0.47) | ADORA1ADORA3ADORA2AADORA2BCYP1A2 | |
| SCHEMBL5083000 | 0.96 | ADORA1 (0.41) | ADORA1ADORA3ADORA2AADORA2BCYP1A2 | |
| SCHEMBL5080069 | 0.85 | CDK1 (0.40) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL5083644 | 0.83 | ADORA1 (0.41) | ADORA1ADORA3ADORA2AADORA2BCYP1A2 | |
| SCHEMBL5083566 | 0.81 | TAS1R3 (0.42) | ADORA1ADORA3ADORA2AADORA2BCYP1A2 | |
| SCHEMBL5080090 | 0.81 | RAB9A (0.40) | ADORA1ADORA2AADORA2BABL1RIN1 | |
| SCHEMBL5086064 | 0.79 | TAS1R3 (0.38) | ADORA1ADORA3ADORA2AADORA2BCYP1A2 | |
| SCHEMBL5082276 | 0.78 | SMN1; SMN2 (0.40) | ADORA2ACYP1A2CYP2D6 | |
| SCHEMBL5082970 | 0.74 | NR2F2 (0.43) | ADORA1ADORA3ADORA2AADORA2BCYP1A2 | |
| SCHEMBL5083017 | 0.72 | ADORA1 (0.43) | ADORA1ADORA3ADORA2AADORA2BCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7388002-B2 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-20060122391-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122391-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | POLR2H, NSUN2, POLR2E | ADORA1 1330/4885ADORA3 170/4885ADORA2A 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.